Regulation of endothelial cell junctions by VEGF and angiopoietin

VEGF 和血管生成素对内皮细胞连接的调节

• 批准号: 8694252
• 负责人: Arie Horowitz
• 金额: $ 39.63万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8694252
• 关键词: Accounting; Actins; Address; Adherens Junction; Angiopoietin-1; Angiopoietins; Atherosclerosis; Binding Proteins; Blood Vessels; Brain; Cardiac; Cells; Code; Cytoplasm; Data; Dependence; Diabetes Mellitus; Disease; Disease Outcome; Drug Targeting; Edema; Endothelial Cells; Extravasation; Eye diseases; Foundations; Genes; Genetic; Glioblastoma; Goals; Guanine; Guanine Nucleotide Exchange Factors; Guanosine Triphosphate Phosphohydrolases; Heart Diseases; Integral Membrane Protein; Intercellular Junctions; Intracranial Hypertension; Ischemia; Knowledge; Lead; Ligands; Macular degeneration; Maintenance; Malignant Neoplasms; Malignant neoplasm of brain; Mediating; Membrane Protein Traffic; Microfilaments; Modeling; Molecular; Morbidity - disease rate; Mus; Outcome; Pathology; Pathway interactions; Pattern; Permeability; Pharmaceutical Preparations; Pharmacotherapy; Process; Property; Proteins; Public Health; Receptor Protein-Tyrosine Kinases; Recruitment Activity; Regulation; Research; Rheumatoid Arthritis; Role; Scheme; Signal Pathway; Signal Transduction; Solid; Stroke; TIE-2 Receptor; Tertiary Protein Structure; Testing; Tight Junctions; Vascular Endothelial Growth Factors; Vascular Permeabilities; Vascular System; Zebrafish; angiogenesis; base; cell motility; cytokine; design; effective therapy; improved; in vivo; innovation; loss of function; mouse model; novel; novel strategies; prevent; protein function; public health relevance; response; stem; therapeutic target; trafficking

DESCRIPTION (provided by applicant): A crucial gap in the understanding of endothelial cell (EC) junction maintenance is the absence of a molecular mechanism to explain how angiopoietin-1 (Ang1) and its receptor, Tie2, stabilize the junctions. Loss of junction integrity i implicated in numerous diseases, including cancer, stroke, diabetes, rheumatoid arthritis, atherosclerosis, cardiac ischemia, and macular degeneration. In such pathologies, vascular endothelial growth factor (VEGF) has a potent disruptive effect on cell junctions and undermines vessel integrity. In contrast, angiopoietin-1 (Ang1) opposes the effect of VEGF and maintains junction integrity. Similar to Ang1, the formin protein mDia has a stabilizing effect on cell junctions, due to its maintenance of the cortical actin ring. We have obtained exciting preliminary results, which support the premise that mDia is an Ang1 effector. Based on these results, our proposal is expected to provide the first detailed account of the antagonistic effects of VEGF and Ang1 on cell junctions. Our central hypothesis is that VEGF and Ang1 regulate EC junctions by determining the spatial pattern of the activities of mDia and Syx (a RhoA-specific guanine exchange factor upstream of mDia) via membrane traffic. We will address this hypothesis by pursuing three specific aims: (1) determining how Ang1 recruits Syx to EC junctions; (2) determining the role of mDia trafficking in Ang1 and VEGF signaling; (3) determining how Syx and mDia regulate Ang1 signaling in a murine model of glioblastoma. To this end, we will use mouse and zebrafish loss-of-function models of several of the genes relevant to these pathways. The potential contribution of this study is significant because it will advance the field conceptually by integrating VEGF and Ang1 signaling into a coherent regulatory mechanism of vessel permeability. This will have a lasting effect on the general understanding of cell-cell junctions. A consequence of the poor knowledge of Ang1 regulation of cell junctions is the scarcity of drugs to target the Ang1 signaling pathway. This putative pathway, leading from Ang1/Tie2 to mDia and to the stabilization of endothelial cell junctions, implicates several proteins that have not been considered before as drug targets. The elucidation of this signaling pathway will provide, therefore, a solid foundation for the design of new therapies to prevent vessel leakage in pathological conditions. As a principal outcome, we will define key checkpoints that will allow us to selectively control VEGF vs. Ang1/Tie2 mediated angiogenesis. These features constitute the potential translational significance of our proposed research. The proposed research is innovative in that it will reveal a novel signaling pathway to explain how Ang1 stabilizes EC junctions, and will incorporate membrane traffic as a novel component of angiogenesis.

描述（由申请人提供）：在内皮细胞（EC）连接维持的理解中，一个关键的空白是缺乏分子机制来解释血管生成素-1 （Ang1）及其受体Tie2如何稳定连接。连接完整性丧失与许多疾病有关，包括癌症、中风、糖尿病、类风湿关节炎、动脉粥样硬化、心脏缺血和黄斑变性。在这些疾病中，血管内皮生长因子（VEGF）对细胞连接具有强大的破坏作用，破坏血管完整性。相反，血管生成素-1 （Ang1）对抗VEGF的作用并维持连接的完整性。与Ang1类似，formin蛋白介质对细胞连接具有稳定作用，这是由于它能维持皮层肌动蛋白环。我们已经获得了令人兴奋的初步结果，支持了media是Ang1效应器的前提。基于这些结果，我们的建议有望提供对拮抗作用的第一个详细说明